Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592208 | SCV000704673 | uncertain significance | not provided | 2017-06-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001088286 | SCV001001278 | likely benign | Nephronophthisis | 2024-12-11 | criteria provided, single submitter | clinical testing | |
Yale Center for Mendelian Genomics, |
RCV001849405 | SCV002106522 | likely pathogenic | Congenital anomaly of kidney and urinary tract | 2018-08-24 | no assertion criteria provided | literature only | |
Genetic Services Laboratory, |
RCV003151110 | SCV003839784 | uncertain significance | not specified | 2022-08-15 | no assertion criteria provided | clinical testing | DNA sequence analysis of the NPHP4 gene demonstrated a sequence change, c.3983C>T, in exon 28 that results in an amino acid change, p.Pro1328Leu. This sequence change has been previously described in the compound heterozygous state in an individual with congenital kidney/urinary tract anomalies (PMID: 30143558). This sequence change has been described in the gnomAD database with a frequency of 0.24% in the African subpopulation and 0.023% in the general population (dbSNP rs199583130). The p.Pro1328Leu change affects a highly conserved amino acid residue. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Pro1328Leu substitution. Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Pro1328Leu change remains unknown at this time. |